Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission (NCT05230173)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis \[UC\]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Arizona — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
- Pragmatic (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (24 Sites)
- Mayo Clinic Arizona — Scottsdale, Arizona
- Hoag Hospital — Irvine, California
- UC San Diego Health — La Jolla, California
- Cedars-Sinai — Los Angeles, California
- Sutter Health — Palo Alto, California
- University of Colorado — Aurora, Colorado
- Yale University — New Haven, Connecticut
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Advent Health — Orlando, Florida
- University of Chicago Medicine — Chicago, Illinois
- Dartmouth Hitchcock — Lebanon, New Hampshire
- Saratoga Schenectady Gastroenterology Associates — Burnt Hills, New York
- NYU Langone Health — New York, New York
- Cornell University — New York, New York
- University of Rochester — Rochester, New York
- Hightower Clinical — Oklahoma City, Oklahoma
- Oregon Clinic — Portland, Oregon
- Gastroenterology Associates — Providence, Rhode Island
- GastroOne — Germantown, Tennessee
- University of Texas Southwestern — Dallas, Texas
- Baylor College of Medicine — Houston, Texas
- University of Utah Health — Salt Lake City, Utah
- University of Virginia — Charlottesville, Virginia
📞 Contact the Study Coordinator
Phone: (480) 301-8000
Email: singh.siddharth@mayo.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ulcerative Colitis
- A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) — Dothan, Alabama
- Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis — San Diego, California
- A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants — Eden Prairie, Minnesota
- CP101 for the Treatment of Ulcerative Colitis — Boston, Massachusetts
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis — Los Angeles, California
- Angiographic Delivery of AD-MSC for Ulcerative Colitis — Rochester, Minnesota
Explore by condition: All Ulcerative Colitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.